18 April 2024 in Genomics, Proteomics & Bioinformatics
Small cell lung cancer (SCLC) is a highly malignant and heterogeneous cancer with limited therapeutic options and prognosis prediction models. Here, we analyzed formalin-fixed, paraffin-embedded (FFPE) samples of surgical resections by proteomic profiling, and stratified SCLC into three proteomic subtypes (S-I, S-II, and S-III) with distinct clinical outcomes and chemotherapy responses. The proteomic subtyping was an independent prognostic factor and performed better than current tumor–node–metastasis or Veterans Administration Lung Study Group staging methods. The subtyping results could be further validated using FFPE biopsy samples from an independent cohort, extending the analysis to both surgical and biopsy samples. The signatures of the S-II subtype in particular suggested potential benefits from immunotherapy. Differentially overexpressed proteins in S-III, the worst prognostic subtype, allowed us to nominate potential therapeutic targets, indicating that patient selection may bring new hope for previously failed clinical trials. Finally, analysis of an independent cohort of SCLC patients who had received immunotherapy validated the prediction that the S-II patients had better progression-free survival and overall survival after first-line immunotherapy. Collectively, our study provides the rationale for future clinical investigations to validate the current findings for more accurate prognosis prediction and precise treatments.
18 November 2025 in Clinical Cancer Research
Purpose: The aim of this study was to evaluate the efficacy of neoadjuvant chemotherapy (albumin-bound paclitaxel + carboplatin) combined with the PD-1 inhibitor tislelizumab in patients with potentially resectable stage II to IVb head and neck squamous cell carcinoma (HNSCC) and explore immune and circulating tumor–related features potentially associated with treatment response. Patients and Methods: This was a single-arm phase II trial involving 33 patients with potentially resectable stage II to IVb HNSCC. Participants received two cycles of neoadjuvant therapy followed by surgery. Primary endpoints were pathologic complete response (pCR) rate and major pathologic response (MPR) rate. Safety and exploratory analyses, including circulating tumor cells (CTC), PD-L1 expression, and T-cell senescence, were also assessed. Results: The study demonstrated an objective response rate of 72.7% (24/33) and an R0 resection rate of 93.1% (27/29) in surgical patients. The pCR rate was 44.8%, and the MPR rate was 62.1%. The laryngeal preservation rate was 70.4% (19/27). With a median follow-up of 20.5 months, the 12- and 24-month event-free survival rates were 93.1% (95% confidence interval, 84.3%–100%). Five of six patients with decreased CTC levels achieved MPR (5/6, 83.3%). Among patients whose T-cell senescence decreased, four of six achieved MPR, whereas only two of five with increased T-cell senescence achieved MPR. The pCR rate was significantly higher in patients with PD-L1 combined positive score ≥ 1 compared with those with combined positive score < 1 (55.6% vs. 12.5%). Conclusions: Neoadjuvant immunochemotherapy improves pathologic response and organ preservation in stage II to IVb HNSCC. Dynamic changes in CTCs and T-cell senescence are associated with treatment efficacy, suggesting their potential as early, noninvasive indicators of response, supporting precision treatment strategies for locally advanced HNSCC.
2 February 2026 in Clinical Nuclear Medicine
Purpose: To evaluate the radioactive distribution patterns of [ 68 Ga]Ga-FAPI-04 in primary hepatocellular carcinoma (HCC). Methods: Twenty-three primary HCC patients (26 lesions) from a prospective trial (ChiCTR2000039099) underwent both [ 18 F]FDG and [ 68 Ga]Ga-FAPI-04 PET/CT within 1 week. Uptake at tumor margins versus centers was compared. Results: FAPI-04 uptake was significantly higher at tumor margins than centers (SUVmax, P <0.001; SUVmean, P <0.01). As SUVmax thresholds increased, FAPI volume of interest concentrated at the margins and decreased sharply in the centers. Conclusions: [ 68 Ga]Ga-FAPI-04 PET/CT demonstrated higher marginal uptake and pronounced central heterogeneity (low-SUV centers) in HCC. Strong peripheral uptake supports the use of FAP-targeted fluorescence-guided surgery and targeted treatment of marginal residual/recurrent disease, while low central uptake may limit FAP-targeted therapy.
1 November 2025 in American Journal of Physiology-Cell Physiology
The Sonic Hedgehog (Shh) signaling pathway is reactivated after myocardial ischemia and regulates cardiac tissue repair. However, the effect of Shh signaling pathway on the biological function of CFs and the mechanism of its regulation have not been clarified. Our results demonstrated that activation of Smo may inhibit the proliferation of CFs and have an antifibrotic effect in vivo. This suggests that the Shh signaling pathway may be a potential therapeutic target for cardiac fibrosis.